Loading financial data...

CUMBERLAND PHARMACEUTICALS INC (CPIX) Financial Statements | Global Financial Data

CUMBERLAND PHARMACEUTICALS INC

CPIXSEC EDGAR

Pharmaceutical Preparations(TN)CIK: 1087294

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$8.5M	$9.2M	$11.2M	$35.0M	$32.4M
Cost of Goods and Services Sold	$6.6M	$6.1M	$9.1M	$8.8M	$7.4M
Research and Development Expense	$4.8M	$5.8M	$6.7M	$5.7M	$6.9M
Operating Income (Loss)	-$1.9M	-$1.5M	-$1.3M	-$324.3K	-$9.3M
Interest Expense	$605.5K	$667.9K	$586.0K	$98.0K	$246.2K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	-$6.3M	-$5.6M	-$5.6M	-$9.3M
Income Tax Expense (Benefit)	-$22.7K	$45.8K	$68.8K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$75.6M	$81.8M	$92.9M	$84.5M	$96.5M
Assets, Current	$36.5M	$35.7M	$45.9M	$45.7M	$50.0M
Cash and Cash Equivalents, at Carrying Value	$18.0M	$18.3M	$19.8M	$27.0M	$24.8M
Accounts Receivable, after Allowance for Credit Loss, Current	$11.7M	$9.8M	$13.2M	$6.9M	$12.4M
Inventory, Net	$4.0M	$4.6M	$9.9M	$8.4M	$10.6M
Liabilities	$53.0M	$52.5M	$57.0M	$41.9M	$49.6M
Liabilities, Current	$31.6M	$28.0M	$28.6M	$19.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$612.2K	$6.1M	$8.5M	$6.3M	$3.1M
Net Cash Provided by (Used in) Investing Activities	$57.8K	-$105.7K	-$13.7M	-$501.9K	$2.3M
Net Cash Provided by (Used in) Financing Activities	$196.9K	-$7.4M	-$2.1M	-$3.6M	-$5.1M
Payments to Acquire Property, Plant, and Equipment	$66.5K	$281.3K	$102.1K	$103.5K	$246.2K
Payments for Repurchase of Common Stock	$579.0K	$740.5K	$1.1M	$1.4M	$3.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)